The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.
 
Vered Stearns
Research Funding - Abbvie; Celgene; MedImmune; Merck; Novartis; Pfizer; Puma Biotechnology
 
Anne M. O'Neill
No Relationships to Disclose
 
Bryan P. Schneider
No Relationships to Disclose
 
David A. Flockhart
No Relationships to Disclose
 
Todd C. Skaar
No Relationships to Disclose
 
Minetta C. Liu
Research Funding - Celgene (Inst); Clearbridge Biomedics (Inst); Eisai (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Veridex (Inst)
 
Caroline A. Lohrisch
No Relationships to Disclose
 
Matthew P. Goetz
No Relationships to Disclose
 
Carlos Vallejos Sologuren
No Relationships to Disclose
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - AstraZeneca; Celgene; Curis; Eisai; Genentech/Roche; Johnson & Johnson; Novartis; Sanofi
Research Funding - Merck (Inst)
 
Diego Villa
No Relationships to Disclose
 
Paula Silverman
No Relationships to Disclose
 
Puneet S. Cheema
No Relationships to Disclose
 
Dennis Frederic Moore
No Relationships to Disclose
 
George W. Sledge
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
Honoraria - Genentech; Symphony Evolution
Consulting or Advisory Role - Nektar; Symphony Evolution
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Nektar